07.01.2026 20:01
👍 3
🔁 1
💬 0
📌 0
Read it here!
Genomic sequencing's integration into healthcare demands new evaluation methods to assess real-world value and support equitable implementation.
by Goranitis I, Hayeems RZ (...) Stark Z et 11 al. in Nat Med #MedSky
👉 get more here
📖 read the article:
The job of a doctor is not, necessarily, to be kind or popular or fluffy or liked.
It is to do and to say the right thing for your patients.
However difficult it may be to do so.
However tough you may find it.
Many institutions pretend otherwise, including the GMC.
Here's why they're wrong 🧵
@ajuntamentbcn.bsky.social
Easy access to diagnostic investigations in primary care is likely to diagnose cancer earlier and prolong patient's lives.
Optimal management of comorbidities is also likely to facilitate access to radical cancer therapies.
NHS cancer funding needs to take the entire picture into account.
Graham Warren on smoking cessation in lung cancer pts.
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.
Translational studies to aid patient selection will now be more needed than ever.
New 5-year data from the CROWN trial in Asian ALK+ #lungcancer: Lorlatinib continues to show longer progression-free survival than crizotinib, with 63% progression-free at 5 years vs. 7% with crizotinib. Strong intracranial response rates too. www.jto.org/article/S155... #LCSM
The 2nd part of the Therapeutics Symposium at #BTOG25 Annual Conference is chaired by
@carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering “Refining Patient Selection”.
btog.org/23rd-btog-an...